Letters to the Editor Low Rates of Side Effects in Paclitaxel Chemotherapy for Kaposi Sarcoma and Feasibility of Treatment in Outpatient ART Clinic Settings in Malawi.
Letters to the Editor Low Rates of Side Effects in Paclitaxel Chemotherapy for Kaposi Sarcoma and Feasibility of Treatment in Outpatient ART Clinic Settings in Malawi.
复制标题
致编辑的信 紫杉醇化疗卡波西肉瘤的副作用发生率低，以及马拉维门诊 ART 诊所治疗的可行性。
DOI：
10.1097/qai.0000000000003393
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Painschab,Matthew
中科院分区：
文献类型：
--
作者：
Rambiki,Ethel;Rambiki,Kelvin;Khalani,Jennipher;Huwa,Jacquiline;Wallrauch,Claudia;Heller,Tom;Painschab,Matthew
由人类疱疹病毒8型（HHV-8）1引起的卡波西肉瘤（KS）是HIV感染者中最常见的癌症。免疫抑制是KS发展的一个重要风险因素，在抗逆转录病毒疗法（ART）治疗广泛应用之前，很大一部分艾滋病毒感染者发展为KS 2。2020年，卡波西肉瘤被列为马拉维第五大最常见癌症，年龄标准化发病率为每10万人10. 9例3。KS的有效管理需要ART和化疗的联合治疗4，5。马拉维临床艾滋病指南（2022年）建议紫杉醇作为晚期KS（T1或禁用T0-Cosmetic或其他）的一线化疗。该指南遵循了2013年至2018年进行的一项多国开放标签临床试验的结果，该试验显示紫杉醇+ ART给药组第48周的无进展生存率高于依托泊苷+ ART或长春新碱+博来霉素+ ART组。
Kaposi sarcoma (KS), caused by human herpes virus 8 (HHV-8) 1, is the most common cancer in HIV infected individuals. Immunosuppression is an important risk factor for KS development and before antiretroviral therapy (ART) treatment became widely available a large proportion of people living with HIV developed KS 2. In 2020, Kaposi sarcoma was ranked as the fifth most common cancer in Malawi with an age-standardized incidence of 10.9 per 100,000 3. Effective management of KS requires combination treatment with ART and chemotherapy 4, 5. The Malawi Clinical HIV guidelines (2022) recommend paclitaxel as first-line chemotherapy for advanced KS (T1 or disabling T0-cosmetically or otherwise). The guidelines are following findings from a multi-national, open-label clinical trial conducted between 2013 to 2018, which showed higher progression free survival rates at week 48 with paclitaxel+ ART administration than in etoposide+ ART or vincristine+ bleomycin+ ART arms 6.